Boston Scientific Recalls Spinal Cord Stimulator Leads Over Fracture Risk
Boston Scientific recalls Infinion CX SCS leads following 1,081 injury reports. Health authorities urge immediate return of unused inventory.
Stocks · News reference
Boston Scientific shares are trading lower after the company disclosed that it identified a cybersecurity incident affecting certain of its information technology systems that disrupted its operations.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Renal Denervation Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)
The global renal denervation market is expected to experience significant growth driven by rising resistant hypertension cases, positive clinical trial results, regulatory approvals, and technological advances in radiofrequency, ultrasound, and micro-infusion technologies. North America currently leads the market while Asia-Pacific is projected to grow fastest. The minimally invasive procedure treats uncontrolled hypertension by disrupting sympathetic nerves surrounding renal arteries.
Boston Scientific shares are trading lower after the FDA disclosed it is aware that the companyissued a letter to affected customers recommending all unused Infinion CX Leads be removed from where they are used or sold.
FDA Says Aware Boston Scientific Issued Letter To Affected Customers Recommending Unused Infinion CX Leads Be Removed From Where They Are Used/Sold; As Of May 27, 2026, Boston Scientific Reported 1,081 Serious Injuries And No Deaths Associated With Issue Related To Infinion CX Leads